This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed
to evaluate microbiological response at the test of cure (ToC) visit along with safety,
tolerability and pharmacokinetic (PK) response following daily oral dosing for 5 days of
GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator
nitrofurantoin will be included in the study to ensure unbiased reporting of safety events.
The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment
period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment
period and PK analysis conducted less frequently, at key trough timepoints.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.